Radioligands for brain imaging of the κ-opioid system

Journal of Nuclear Medicine

Volumn 46, Issue 3, 2005, Pages 386-387

  Machulla, Hans Jürgen ^a   Heinz, Andreas ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(3,4 DICHLOROPHENYL)ACETYL] 3 (1 PYRROLIDINYLMETHYL) 1 PIPERAZINECARBOXYLIC ACID METHYL ESTER; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NALOXONE; NALTREXONE; RADIOLIGAND; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ALCOHOLISM; ALZHEIMER DISEASE; COCAINE DEPENDENCE; DOPAMINE RELEASE; EPILEPSY; FUNCTIONAL STATUS; GILLES DE LA TOURETTE SYNDROME; HEROIN DEPENDENCE; HUMAN; LIGAND BINDING; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SHORT SURVEY; ANIMAL; BRAIN; DEGENERATIVE DISEASE; IMAGE ENHANCEMENT; METABOLISM; METHODOLOGY; NOTE; SCINTISCANNING;

ANIMALS; BIOLOGICAL MARKERS; BRAIN; HUMANS; IMAGE ENHANCEMENT; NEURODEGENERATIVE DISEASES; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECEPTORS, OPIOID, KAPPA;

EID: 17844377351     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (18)

1. Carlezon WA, Thome J, Olson VG, et al. Regulation of cocaine reward by CREB. Science. 1998; 282:2272-2275.
2. Cowen MS, Lawrence AJ. The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption. Prog Neuropsychopharmacol Biol Psychiatry. 1999;23:1171-1212.
3. 11C-GR103545, a radiotracer for imaging κ-opioid receptors in vivo with PET: synthesis and evaluation in baboons J Nucl Med. 2005;46:484-494.
4. Spanagel R, Herz A, Shippenberg TS. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA. 1992;89:2046-2050.
5. Staley JK, Rothman RB, Rice KC, Partilla J, Mash DC. κ2 opioid receptors in limbic areas of the human brain are upregulated by cocaine in fatal overdose victims. J Neuroscience. 1997;17:8225-8233.
6. Todtenkopf MS, Marcus JF, Portoghese PS, Carlezon WA Jr. Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology (Berl). 2004;172:463-470.
7. Marinelli PW, Kiianmaa K, Gianoulakis C. Opioid propeptide mRNA content and receptor density in the brains of AA and ANA rats. Life Sci. 2000;66: 1915-1927.
8. De Waele JP, Kiianma K, Gianoulakis C. Spontaneous and ethanol-stimulated in vitro release of β-endorphin by the hypothalamus of AA and ANA rats. Alcohol Clin Exp Res. 1994;18:1468-1473.
9. Bencherif B, Wand GS, McCaul ME, et al. Mu opiate receptor binding measured by [C11]-carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biol Psychiatry. 2004;55:255-262.
10. 11C]carfentanil PET study. Arch Gen Psychiatry. 2005;62:57-64.
11. O'Malley SS, Croop RS, Wroblewski JM, Labriola DF, Volpicelli JR. Naltrexone in the treatment of alcohol dependence: a combined analysis of two trials. Psychiatric Ann. 1995;25:681-688.
12. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;345:1734-1739.
13. Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism. Arch Gen Psychiatry. 2003;60:92-99.
14. Mathieu-Kia AM, Fan LQ, Kreek MJ, Simon EJ, Hiller JM. Mu-, delta- and kappa-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer's disease patients. Brain Res. 2001;893:121-134.
15. Chappell PB, Leckman JF, Scahill LD, Hardin MT, Anderson G, Cohen DJ. Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: a pilot study. Psychiatry Res. 1993;47:267-280.
16. 3H]U69,593 binding in the human epileptogenic hippocampus. Epilepsy Res. 1997;28:189-205.
17. Chen TY, Goyagi T, Toung TJ, et al. Prolonged opportunity for ischemic neuroprotection with selective kappa-opioid receptor agonist in rats. Stroke. 2004;35:1180-1185.
18. Naylor A, Judd DB, Lloyd JE, Scopes DI, Hayes AG, Birch PJ. A potent new class of k-receptor agonist: 4-substituted 1-(arylacetyl)-2-[(dialkylamino)- methyl]piperazines. J Med Chem. 1993;36:2075-2083.